Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

Jr Howard J.F., K. Utsugisawa, M. Benatar, H. Murai, R.J. Barohn, I. Illa, S. Jacob, J. Vissing, T.M. Burns, J.T. Kissel, S. Muppidi, R.J. Nowak, F. O'Brien, J.-J. Wang, R. Mantegazza, C.G. Mazia, M. Wilken, C. Ortea, J. Saba, M. RugieroM. Bettini, G. Vidal, A.D. Garcia, P. Lamont, W.-K. Leong, H. Boterhoven, B. Fyfe, L. Roberts, M. Jasinarachchi, N. Willlems, J. Wanschitz, W. Löscher, J. De Bleecker, G. Van den Abeele, K. de Koning, K. De Mey, C. Miranda, S. Bonanno, C. Antozzi, L. Maggi, A. Campanella, C. Angelini, P. Cudia, V. Pegoraro, F. Bevilacqua, R. Iorio, M. Gabriele, S. Messina, A. Amato, S. Scala

Research output: Contribution to journalArticle

Cite this

Howard J.F., J., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., Muppidi, S., Nowak, R. J., O'Brien, F., Wang, J-J., Mantegazza, R., Mazia, C. G., Wilken, M., Ortea, C., Saba, J., ... Scala, S. (2017). Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. The Lancet Neurology, 16(12), 976-986. https://doi.org/10.1016/S1474-4422(17)30369-1